Form 4 Moderna, Inc. For: Apr 28 Filed by: Nader Francois
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Wolfe Research Continues to Favor Moderna's (MRNA) 'Significiant Upside Optionality' in its Broad Pipeline
May 4, 2022 10:22 AM EDTWolfe Research analyst Andrew Galler reiterated an Outperform rating and $261.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "At the time of our initiation in November 2021, the stock was coming off of a onetwo punch from a cut to COVID vaccine guidance and PFEs topline data for Paxlovid from the EPIC-HR study, but with increasing visibility into the booster opportunity (which has only been helped by the spread of the Omicron variant), the... More
